A Phase II Single-Arm Multi-Center Trial Evaluating the Efficacy of Pembrolizumab in the Treatment of Subjects With Incurable Platinum-Refractory Germ Cell Tumors: Hoosier Cancer Research Network GU14-206

Trial Profile

A Phase II Single-Arm Multi-Center Trial Evaluating the Efficacy of Pembrolizumab in the Treatment of Subjects With Incurable Platinum-Refractory Germ Cell Tumors: Hoosier Cancer Research Network GU14-206

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Oct 2017

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Germ cell and embryonal neoplasms
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Oct 2017 Results (n=12) assessing efficacy and safety of pembrolizumab in patients with incurable platinum refractory germ cell tumors, were published in the Annals of Oncology.
    • 06 Jun 2017 Results (n=12) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 01 Feb 2017 Planned End Date changed from 1 Jan 2019 to 31 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top